Platinum-free triplet therapy with nab-paclitaxel, S-1, and tislelizumab as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma: a phase ii single-arm trial.

BMC Cancer · 2026 · PMC13134346 · PMID 41840368

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.0880

boldest claim

The sentences

a strong trendP = 0.050actually significant

Patients who underwent surgery experienced a strong trend toward improved overall survival (OS) (median 29.5 months vs. 18.3 months, HR: 0.42, 95% CI: 0.20–0.90, P = 0.050).

also in 5,725 other papers

did not reach statistical significanceP = 0.088so close (0.05 < p ≤ 0.1)

In a complementary Cox model treating conversion surgery as a time-varying covariate using the observed surgery times, conversion surgery remained associated with improved PFS (HR, 0.32; 95% CI, 0.11–0.95; P = 0.041), whereas the association with OS was directionally favorable but did not reach statistical significance (HR, 0.40; 95% CI, 0.14–1.15; P = 0.088).

also in 111,027 other papers

showed a trendno p-value reported

Patients older than 65 years, with stomach tumor location, mixed type, moderately differentiated degree or with retroperitoneal lymph nodes metastatic site showed a trend toward higher ORRs (Table S1).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.